In8Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. The company leverages its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, collectively referred to as the DeltEx platform, to create innovative…
In8Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. The company leverages its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, collectively referred to as the DeltEx platform, to create innovative therapies. This approach enables In8Bio to expand gamma-delta T cells ex vivo for therapeutic dosing, harnessing their unique ability to recognize cellular stress signals on tumor cells and bridge innate and adaptive immunity.
As a clinical-stage company, In8Bio has not yet generated product sales or revenue from commercialized therapies. The company’s financial strategy relies on raising capital through public offerings, private placements, and potential strategic partnerships to fund ongoing clinical trials, research and development, manufacturing scale-up, and regulatory activities. Revenue generation is anticipated only upon successful regulatory approval and commercialization of its product candidates, which remain in preclinical or clinical development stages.
The company operates through the following segments:
- DeltEx Allogeneic (Allo) gamma-delta T cell therapy: This segment focuses on developing donor-derived, expanded, and activated gamma-delta T cells without additional genetic modification for hematologic malignancies. The lead product candidate, INB-100, is being evaluated in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation. Clinical data have shown durable complete remission in acute myeloid leukemia patients, with 100% of AML patients remaining in complete remission across original and expansion cohorts as of February 2025, with a median follow-up of 20.1 months.
- DeltEx Drug Resistant Immunotherapy (DRI): This segment involves genetically engineering gamma-delta T cells to resist cytotoxic effects of standard-of-care chemotherapies, enabling combination therapy for solid tumors. The lead candidate, INB-200, targets newly diagnosed glioblastoma and is designed to confer resistance to temozolomide via MGMT gene expression. Consolidated data from INB-200 (Phase 1) and INB-400 (Phase 2) trials show patients receiving repeated DeltEx DRI gamma-delta T cells achieved a median progression-free survival of 13.0 months and median overall survival not reached (17.2+ months) as of December 31, 2025.
- Gamma-delta T cell engager (TCE) platform: This segment develops proprietary TCEs that activate and expand both Vd1+ and Vd2+ gamma-delta T cell subsets through the gamma-delta T cell receptor. The lead candidate, INB-619, targets CD19 for B-cell-driven autoimmune diseases and oncology applications. Preclinical data presented at the American College of Rheumatology Convergence 2025 demonstrated equivalent in vitro potency to blinatumomab and mosunetuzumab in B-cell depletion, with a favorable cytokine profile showing minimal to no detectable CRS-associated cytokines such as IL-6.
In8Bio positions itself as the most clinically advanced gamma-delta T cell-focused company, leveraging its DeltEx platform to address limitations of conventional CAR-T and NK cell therapies, such as antigen escape, immunosuppressive tumor microenvironments, and cytokine release syndrome. The company differentiates itself through its ability to engineer gamma-delta T cells for chemotherapy resistance, broad tumor recognition via stress ligand detection, and dual activation of Vd1+ and Vd2+ T cell subsets for enhanced persistence and antitumor activity. Competitors in the gamma-delta T cell and TCE space include Adicet Bio, Inc., Century Therapeutics, Inc., Immatics Biotechnologies GmbH, and various TCE-focused firms such as AbCellera Biologics Inc., Amgen Inc., and BioNTech SE, though In8Bio emphasizes its clinical proof-of-concept in leukemia and glioblastoma as a key advantage.
In8Bio serves patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, newly diagnosed glioblastoma patients, and individuals with B-cell-driven autoimmune diseases such as systemic lupus erythematosus. The company’s therapeutic candidates are intended for use in hospital and clinical trial settings, administered by healthcare professionals at specialized cancer centers and academic medical institutions involved in its investigator-sponsored and corporate-sponsored trials.